TobaccoReporter logo

Blog

  • Luersman Joins Imperial Board

    Luersman Joins Imperial Board

    Abbe Luersman will join the Imperial Brands’ board as a nonexecutive director, effective January 12, 2026, according to a press release.

    Luersman, who is chief human resources officer of Walgreens Inc., has had a career as an HR leader in global listed businesses including Otis Worldwide Corporation, Koninklijke Ahold Delhaize NV, Unilever, and Whirlpool Corporation. She is also a nonexecutive director and remuneration committee chair at Just Eat Takeaway NV and co-chair of the Gartner CHRO Global Leadership Board.

    Thérèse Esperdy, chair of Imperial Brands, said, “On behalf of the board, I am delighted to welcome Abbe to Imperial. Abbe has a proven track record in organizational design, integration and cultural change—both as a chief people officer and a nonexecutive director. She has transferred her skills across different sectors, including consumer goods, retail, manufacturing, and industrial technology. Abbe brings deep and wide-ranging experience in transformation programs, an area of strategic importance for Imperial Brands. The board will benefit greatly from her insights and experience, and we look forward to working with her.”

    Luersman will become a member of the Remuneration and the People, Governance and Sustainability Committees upon joining the board.

  • WHO Facing Crises of Relevance, Former Director Says

    WHO Facing Crises of Relevance, Former Director Says

    Dr. Tikki Pang, a professor and former Director of Research Policy and Cooperation at the World Health Organization (WHO), delivered a compelling keynote at the Global Tobacco and Nicotine Forum (GTNF) in Brussels, urging the global public health community to “find a detour” around entrenched opposition to tobacco harm reduction (THR). Drawing a vivid analogy, Pang said the WHO’s position acts like a “landslide blocking the road” to progress, creating ripple effects that influence policy, weaken public trust, and stigmatize innovation. Attempts to change this stance, he said, have proven “frustrating and futile.”

    “‘Tobacco control’ has become the complete elimination of tobacco in society,” Pang said. “It’s become pretty much ideological at this point. It has become evidence-selective, perhaps evidence-blind.

    “We need to overcome this perception that the industry is the cause of the problem and not part of the solution.’

    Pang described the journey toward a THR-friendly world as “a long road with many obstacles,” and warned that the EU’s recent alignment with anti-THR policies could have “global repercussions.” Instead, he called for a “circuit breaker” — independent, multi-stakeholder platforms that operate outside the WHO’s Conference of the Parties (COP) framework. These coalitions should unite industry, consumers, investors, media, and advocates to advance harm reduction directly, he said.

    Pang emphasized the crucial role of media and advocacy in countering misinformation, noting that journalists can either “spread misconceptions or become powerful allies.” He also suggested situating THR within the broader context of non-communicable disease (NCD) prevention.

    Reflecting on his 13 years at the WHO, Pang acknowledged its achievements in supporting underserved populations but said the organization now faces “a crisis of relevance and confidence.” He concluded that while the WHO’s mission explicitly includes improving global health — including for smokers seeking better alternatives — progress will depend on using science-driven innovation and rational policy to achieve that goal.

    “Science has given us the tools to reduce harm from tobacco,” Pang said. “Reason dictates that we should use them.”

  • Examining the U.S. Regulatory Landscape

    Examining the U.S. Regulatory Landscape

    At the Global Tobacco and Nicotine Forum (GTNF) in Brussels, industry leaders examined the shifting regulatory climate in the United States, where overlapping state and federal actions continue to shape — and complicate — the tobacco and nicotine marketplace. The session was moderated by Paige Magness, Senior Vice President of Regulatory Affairs at Altria Client Services, with insights from Beth Oliva, a partner at Fox Rothschild, Laura Leigh Oyler, the Vice President of Regulatory at Haypp Group, Valerie Briggs Solomon, the Vice President of Scientific and Public Health Affairs at Reynolds American, and Dr. Jessica Zdinak, the founder and Chief Research Officer at Applied Research and Analysis Company (ARAC).

    Magness opened the panel, noting that “a change was inevitable” with the new U.S. administration, citing an encouraging shift toward addressing illicit markets. She commended the Tobacco Control Act’s intention but said, “It’s FDA’s implementation where things fall apart.”

    Oyler highlighted the fragmented nature of the U.S. system: “Sometimes it’s hard to remember the U.S. isn’t one big monolith — it’s 50 states that can directly conflict with the federal government.” She stressed that effective youth prevention starts with adult behavior, adding, “The biggest predictor of youth use is whether their parents use. Help the kids by helping their parents make better decisions.”

    Oliva described a growing disconnect between FDA oversight and state-level actions, noting California’s comprehensive flavor ban. “The FDA is the barrier to entry, the states are barriers to the shelf,” she said. “Today they are combining in ways never meant to happen.” Oliva argued that the FDA’s shifting authorization process and policy reversals have destabilized the marketplace, pushing consumers toward illicit products. “Unless we see a lot more authorizations for nicotine products, we’re going to see what happened with e-cigarettes all over again,” she warned. She urged the FDA to “partner with those tracking the data” and to “stop manipulating the industry and consumers in the process.”

    Zdinak focused on the disconnect between regulation, consumer understanding, and behavioral science. “Congress is making laws without understanding the people they govern,” she said, pointing to misinformation about relative risk. She argued that variety and flavor choice drive switching and, therefore, public health gains. “If CTP can’t communicate quickly, the market will move ahead without them,” she cautioned, predicting “another wild west” scenario similar to what happened with the e-cigarette category.

    Solomon criticized the FDA’s tendency to exaggerate youth-use trends while ignoring adult harm reduction. “FDA is calling things an epidemic that aren’t,” she said. “Scaring children away might be good, but scaring adults away from better options is counterproductive.” She underscored the importance of credible communication through trusted messengers: “[The nicotine industry is] not always trusted, so we have to equip those who are. Science will lead the way — if we let it.”

    Overall, the panel agreed that while the U.S. has one of the world’s most comprehensive regulatory systems, its complexity and inconsistency risk stifling innovation and harming public health goals. The consensus was that greater collaboration, transparency, and scientific grounding are urgently needed to make the regulatory system work for both consumers and harm reduction.

  • EU TPD Panel: Coherence or Patchwork

    EU TPD Panel: Coherence or Patchwork

    At the Global Tobacco and Nicotine Forum (GTNF) in Brussels, industry and policy experts debated whether the EU Tobacco Products Directive (TPD) will promote coherence or wlll result in a regulatory patchwork across member states. The session featured Michiel Reerink of Alliance One International, Nathalie Darge of Tobacco Europe, and environmental risk analyst David Zaruk (“The Risk Monger”).

    Reerink noted that the EU’s regulatory approach has often leaned toward prohibition, arguing that “the EU’s solution was to ban the product.” He said the first TPD brought together older directives but created optional provisions that evolved into regulatory barriers. He emphasized that consistent, science-based regulation would benefit all stakeholders.

    Darge highlighted structural challenges within the European Commission’s previous consulants, citing a lack of neutrality and potential conflicts of interest. She outlined the expected timeline for the next revision, TPD3, with an initial report and proposal anticipated before 2029, followed by member state consultations and a final version possibly by 2030. Darge stressed that policymakers want a stronger voice in shaping the outcome.

    Zaruk warned that the EU’s growing use of the “precautionary principle” as a risk-management tool risks stifling innovation and redefining the very scope of tobacco regulation — “the EU is defining nicotine as tobacco now,” he said. He also criticized the inconsistency of political leadership, arguing that motivated commissioners can drive major policy shifts, while others avoid engagement.

    Panelists agreed that while political volatility, tax pressures, and public sentiment make tobacco an easy target for revenue generation, meaningful progress depends on coherent, evidence-based regulation that balances health goals with economic and consumer realities.

    The GTNF is the world’s leading annual conference discussing the future of the tobacco and nicotine industries. It is the global exchange for views and ideas between public health experts, government representatives, the industry, and investors.

  • BAT’s Wheaton Calls for Policymakers to Embrace Harm Reduction at GTNF Opening

    BAT’s Wheaton Calls for Policymakers to Embrace Harm Reduction at GTNF Opening

    Brussels, October 6, 2025 — Kingsley Wheaton, Chief Corporate Officer of BAT, opened the Global Tobacco and Nicotine Forum (GTNF) with a call for policymakers to embrace harm reduction and real-world evidence as the basis for future regulation.

    “Right now, we stand at a crossroads,” Wheaton said. “One where the choices we make — as individuals, as companies, and as an industry — will shape the future of public health, policy, and perception.”

    Speaking under the GTNF’s theme, “Real World Evidence: The Race to Reduce Harm,” Wheaton argued that Sweden’s near smoke-free status demonstrates the effectiveness of tobacco harm reduction. He credited awareness campaigns, consumer access to smokeless products, and progressive regulation for driving smoking rates to among Europe’s lowest.

    “Sweden is on the verge of achieving something extraordinary: a smoking rate of just 5.3%—less than a quarter of the EU average,” he said. “This isn’t just a number. It’s a public health milestone. And it’s a powerful validation of a strategy that many dismissed: harm reduction.

    “Despite decades of global anti-smoking campaigns, 1 billion people still smoke. At BAT, we believe quitting is the best choice any smoker can make. But for those who won’t quit, offering scientifically substantiated, reduced-risk alternatives is essential. Sweden proves this approach works.”

    In his remarks, Wheaton touted the success of BAT’s Omni program, the company’s global platform and manifesto for tobacco harm reduction launched in 2024. He said Omni is both a movement and a communications framework through which BAT promotes its vision of a “Smokeless World,” aiming to make smokeless products mainstream and push for regulatory environments that support harm reduction.

    “With Omni, we’re launching a platform for science, dialogue, and collaboration to accelerate progress toward a smokeless world,” Wheaton said. “This transformation took belief—belief that we could be part of the solution. And today, I’m proud to say: we were right to believe in it.

    Wheaton also criticized prohibitionist policies, pointing to Australia’s illicit market as evidence of unintended consequences when safer alternatives are restricted. He urged EU policymakers to adopt proportionate, risk-based regulation that recognizes harm reduction as part of tobacco control.

    “How can policymakers not see what’s right in front of their eyes?” Wheaton said. “When safer alternatives are blocked, the void is filled by danger, not progress. It’s time to rethink, recalibrate, and reclaim the narrative. So perhaps it’s time to ask: What if the most effective way to end smoking isn’t to fight nicotine, but to reimagine it? What if the companies that once sold cigarettes can now lead the charge to make them obsolete?

    “The WHO continues to ignore and sideline harm reduction, clinging to outdated dogma while real-world evidence piles up. This is not just intransigence, it’s negligence. It’s time for policymakers to stop pretending this evidence doesn’t exist. Seventy percent of policy experts still believe nicotine is the primary cause of smoking-related diseases, like cancer. That’s not just inaccurate, it’s dangerous. If we’re serious about closing the Tobacco Harm Reduction deficit, we must engage directly with regulators, health authorities, and policy experts to ensure that safer alternatives are not just available, but understood, accepted, and encouraged.”

    The GTNF is the world’s leading annual conference discussing the future of the tobacco and nicotine industries. It is the global exchange for views and ideas between public health experts, government representatives, the industry, and investors.

  • What Role Does the FCTC Play in Today’s Regulatory Environment?

    What Role Does the FCTC Play in Today’s Regulatory Environment?

    At the Global Tobacco and Nicotine Forum (GTNF) in Brussels, an expert panel explored the growing disconnect between the World Health Organization’s Framework Convention on Tobacco Control (FCTC) and real-world tobacco harm reduction (THR) progress. The session featured Dr. Derek Yach, global health advocate and former WHO executive; Peter Beckett, Co-Founder of Clearing the Air; Dr. Tikki Pang, a professor and former WHO Director of Research Policy and Cooperation; and Dr. Christopher Snowdon, Head of Lifestyle Economics at the Institute of Economic Affairs.

    Yach opened the discussion by criticizing the gap between FCTC policymaking and on-the-ground data. He noted that smoking rates are falling faster in countries embracing harm reduction — such as the U.S., U.K., Japan, South Korea, and New Zealand — than under traditional tobacco control strategies. “If it can happen in Pakistan, it can happen in all of Southeast Asia,” he said. “And if it happens in Southeast Asia, we could be seeing oral cancer in the rearview mirror.” Yach emphasized the need for collaborative public–private partnerships to ensure product safety and credibility, while urging policymakers to move beyond what he called the “distraction” of youth-related arguments that ignore the millions of adult smokers seeking alternatives.

    “It’s not that youth use isn’t important, but putting all the attention on kids doesn’t help for 50 years,” he said. “What about their parents? We could be adding years to their lives right now. [Anti-THR people] just use the youth as a way to divide the argument. We need to shift to the data and take the kid issue off the table.”

    Beckett took a blunt tone, arguing that the FCTC framework is obsolete, exclusive, and lacking transparency. He said the WHO’s current approach alienates the public and damages its credibility, calling the situation “chaotic,” which makes it easier for harm-reduction advocates to push back on. Beckett urged reform-minded countries — especially WHO funders — to “recognize the world as it is” and resist “bullying by overpaid foundations with an agenda,” and accused prohibitionist groups of crossing the line.

    “Ten years ago, they were disingenuous; now they’re straight-up lying,” he said. “I keep hearing the same damn thing. ‘We need to engage with science, we need to be nice to the other side.’ I’m calling bullshit on that. It doesn’t work. There is no amount of science that will do the job. If there was, they’d let me in the bloody room when they have these conversations. We have to recognize this and say enough, and call for a tearing down of the framework in its entirety, because it’s not salvageable.”

    Pang reiterated that many developing countries adopt WHO guidance without generating or analyzing their own data. “They take the easy way out,” he said, “because they lack the capacity to build evidence locally.” Pang pointed to emerging “pockets of positive thinking” among countries that are now re-evaluating WHO recommendations and embracing THR. He called for greater industry unity — across state-owned, multinational, and startup sectors — and stronger alignment with consumer voices. “Consumers are also voters,” he reminded the audience, “and together they can influence policy.”

    Snowdon warned of troubling developments within the WHO, citing “endgame” proposals that reject harm reduction as an industry “con.” He described this as a “quasi-religious mission to destroy all tobacco,” resistant to evidence and reason. Snowdon noted that while grassroots THR advocacy exists, it ironically remains underfunded and overshadowed by well-resourced opposition.

    “We are greatly out-financed. The industry can contribute, but then we get ostracized,” he said. “We have a genuine grassroots movement, but these people have lives to live. They can’t be doing it all the time. Meanwhile, the other side has unlimited resources. The media could be helpful, but they don’t want to risk it.”

    Across the panel, a consensus emerged: the WHO’s FCTC framework risks irrelevance unless it adapts to include harm reduction. Participants agreed that the future of global health policy must be driven by data, innovation, and collaboration rather than ideology.

    The GTNF is the world’s leading annual conference discussing the future of the tobacco and nicotine industries. It is the global exchange for views and ideas between public health experts, government representatives, the industry, and investors.

  • Illicit Cigarettes Still Increasing in Philippines

    Illicit Cigarettes Still Increasing in Philippines

    Illicit cigarettes in the Philippines are still on the rise, according to PhilStar. The latest market survey shows that illicit cigarettes can be bought for PHP3 to PHP4 ($0.05 to $0.06) per stick. The lowest priced legal brand is PHP7 per stick.

    One of every five cigarettes sold comes from an illegal source. Illicit cigarette trade was 7.4 percent of total volumes in 2021, and in 2025, illicit cigarette trade is at 20.9 percent. Smoking prevalence has also increased from 18.5 percent of adults in 2021 to 23.2 percent in 2025. Youth smoking has doubled from 2.3 percent to 4.8 percent.

    The Philippines Bureau of Internal Revenue estimates that the country loses at least PHP50 billion annually from smuggling and illegal manufacturing.

    Legal cigarette production dropped from 62.6 billion sticks in 2021 to 39.1 billion in 2025.

    According to PhilStar, illicit cigarettes contain harmful chemicals like cadmium, lead, and contaminants like insect parts and human waste. Counterfeit “tuklaw” cigarettes contain synthetic cannabinoids, which have led to severe health issues.

  • Philip Morris Voluntarily Delists from Pakistan Stock Exchange

    Philip Morris Voluntarily Delists from Pakistan Stock Exchange

    The Pakistan Stock Exchange (PSX) has accepted the voluntary delisting request from Philip Morris from its index, reports Dawn.

    Philip Morris is one of the leading tobacco companies operating in Pakistan. The company was voluntarily delisted under PSX Regulation 5.14 and Section 19(5) of the Securities Act, 2015. The delisting is effective Oct. 6.

    “The shareholders of the company, who may desire to avail the opportunity of buy back of shares by the sponsors, are advised to approach Topline Securities,” according to a press release. “The purchase agent and sponsor of the company have already submitted an undertaking to purchase the remaining shares held by the minority shareholders at a price of PKR1,300 ($4.58) per share, which is valid up to September 29, 2026.”

  • Six Manufacturers Appeal MDOs

    Six Manufacturers Appeal MDOs

    Six small manufacturers—American Vapor Company, Breeze Smoke, Elite Brothers, Lead by Sales (doing business as White Cloud Cigarettes), Vapermate, and Vertigo Vapor (doing business as Baton Vapor)—have filed appeals against the U.S. Food and Drug Administration’s marketing denial orders (MDOs), according to Vaping360.

    The companies all received MDOs between May 2024 and June 2025 and filed petitions for review in the Fifth Circuit within 30 days.

    While American Vapor Company is the only petitioner located within the Fifth Circuit’s jurisdiction, the other manufacturer’s recruited retail co-petitioners located within the jurisdiction, as allowed by the Supreme Court earlier this year. The Fifth Circuit has consolidated the cases as they are challenging on the same grounds and share the same attorneys.

    Azim Chowdhury and Eric Gotting of Keller and Heckman are representing the companies.

  • Survey: Most Policy Experts Misidentify Nicotine Risks

    Survey: Most Policy Experts Misidentify Nicotine Risks

    A new multi-market survey of policy experts across 15 different territories reveals that erroneous perceptions of nicotine health risks continue to persist, despite both the growing scientific consensus that nicotine is not a primary cause of smoking-related disease and the increased availability of smokeless alternatives to conventional cigarettes, according to BAT.

    The survey, commissioned by British American Tobacco (BAT) and released ahead of the start of this year’s GTNF in Brussels this week, reveals that seven in 10 policy experts continue to incorrectly believe nicotine is the main cause of smoking-related disease.

    In addition, the research—which interviewed three cohorts (Nicotine Users; Policy Experts; and Medical Professionals) in 2024 and 2025—also found that while half of medical professionals discussed smokeless alternatives to cigarettes weekly with their patients, only 21% feel well-informed enough to recommend them.

    Kingsley Wheaton, Chief Corporate Officer at BAT, said: “This survey shows that while change is possible, it’s not a given. We’re seeing green shoots of progress, especially where we’ve launched new product innovations and invested in clear, science-led communication. But the data also tells us we must go further and faster and equip those making decisions with the latest scientific evidence about smokeless products.

    “We remain committed to working with public health authorities, regulators and scientists to ensure accurate information reaches consumers.”

    Conducted by a third party on behalf of BAT, the research did show indications of improved perception of smokeless products, in particular vapor products among nicotine users.